19941

    524500

    KILITCH

    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    KILITCH DRUGS INDIA LTD Share Price Today

    KILITCH DRUGS INDIA LTD is currently trading at ₹190, up by ₹3.41 from the previous close. The stock touched an intraday high of ₹192.00 and a low of ₹185.00 during the latest trading session. Over the past one year, KILITCH DRUGS INDIA LTD has delivered a loss of 15.37%, while the stock has declined 4.18% in the last one month.

    KILITCH DRUGS INDIA LTD performance

    Today’s low Today’s high
    ₹ 185.00 ₹ 192.00
    ₹ 190.70
    52 week low 52 week high
    ₹ 117.25 ₹ 227.23
    ₹ 190.70
    Open Price ₹ 192.00
    Prev. Close ₹ 186.59
    Volume (Shares) 8369.00
    Total traded value ₹ 15.95
    Upper Circuit ₹ 195.91
    Lower Circuit ₹ 177.27
    info

    Investment Returns

    Over 1 Month -4.18% Over 3 Months 21.14% Over 6 Months 15.12% Over 1 Year -15.37%
    Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    KILITCH DRUGS INDIA LTD fundamentals


    • Market cap (Cr) 666.70
    • P/E Ratio (TTM) 20.47
    • Beta 1.06
    • Book Value / share 95.25
    • Return on equity 11.02%
    • EPS (TTM) 9.27
    • Dividend yield 0.00%
    • Net profit/quarter (Cr) 14.00
    info icon alternate text
    • Market cap (Cr) 650.80
    • P/E Ratio (TTM) 20.47
    • Beta 0.90
    • Book Value / share 95.25
    • Return on equity 11.02%
    • EPS (TTM) 9.27
    • Dividend yield 0.00%
    • Net profit/quarter (Cr) 14.00
    info icon alternate text

    KILITCH DRUGS INDIA LTD Financials

    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 71.97
    Operating Expense 53.78
    Net Profit 14.00
    Net Profit Margin (%) 19.45
    Earnings Per Share (EPS) 4.08
    EBITDA 20.60
    Effective Tax Rate (%) 27.57
    Particulars DEC 2025 (Values in Cr)
    Revenue 44.67
    Operating Expense 40.11
    Net Profit 4.89
    Net Profit Margin (%) 10.94
    Earnings Per Share (EPS) 2.74
    EBITDA 7.33
    Effective Tax Rate (%) 20.74
    Particulars SEP 2025 (Values in Cr)
    Revenue 37.81
    Operating Expense 35.35
    Net Profit 8.72
    Net Profit Margin (%) 23.06
    Earnings Per Share (EPS) 5.27
    EBITDA 11.28
    Effective Tax Rate (%) 13.50
    Particulars JUN 2025 (Values in Cr)
    Revenue 34.12
    Operating Expense 31.64
    Net Profit 4.79
    Net Profit Margin (%) 14.03
    Earnings Per Share (EPS) 2.98
    EBITDA 7.07
    Effective Tax Rate (%) 19.89
    Particulars MAR 2025 (Values in Cr)
    Revenue 56.30
    Operating Expense 43.62
    Net Profit 11.37
    Net Profit Margin (%) 20.19
    Earnings Per Share (EPS) 7.07
    EBITDA 16.23
    Effective Tax Rate (%) 24.13
    Particulars MAR 2026 (Values in Cr)
    Revenue 188.57
    Operating Expense 160.87
    Net Profit 32.40
    Net Profit Margin (%) 17.18
    Earnings Per Share (EPS) 9.57
    EBITDA 46.27
    Effective Tax Rate (%) 22.02
    Particulars MAR 2025 (Values in Cr)
    Revenue 181.59
    Operating Expense 154.62
    Net Profit 31.16
    Net Profit Margin (%) 17.15
    Earnings Per Share (EPS) 19.37
    EBITDA 44.56
    Effective Tax Rate (%) 23.42
    Particulars MAR 2024 (Values in Cr)
    Revenue 131.60
    Operating Expense 114.44
    Net Profit 17.57
    Net Profit Margin (%) 13.35
    Earnings Per Share (EPS) 11.03
    EBITDA 26.50
    Effective Tax Rate (%) 24.75
    Particulars MAR 2023 (Values in Cr)
    Revenue 117.78
    Operating Expense 102.94
    Net Profit 15.72
    Net Profit Margin (%) 13.34
    Earnings Per Share (EPS) 10.09
    EBITDA 21.77
    Effective Tax Rate (%) 19.17
    Particulars MAR 2022 (Values in Cr)
    Revenue 105.16
    Operating Expense 95.78
    Net Profit 10.53
    Net Profit Margin (%) 10.01
    Earnings Per Share (EPS) 6.76
    EBITDA 15.55
    Effective Tax Rate (%) 24.40
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 125.81
    ROE % 11.68
    ROCE % 15.57
    Total Debt to Total Equity 0.21
    EBITDA Margin 19.63
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 109.62
    ROE % 8.28
    ROCE % 13.30
    Total Debt to Total Equity 0.16
    EBITDA Margin 18.62
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 94.08
    ROE % 5.70
    ROCE % 10.24
    Total Debt to Total Equity 0.15
    EBITDA Margin 14.79
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 89.26
    ROE % 4.03
    ROCE % 6.34
    Total Debt to Total Equity 0.13
    EBITDA Margin 10.55
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 82.05
    ROE % 2.41
    ROCE % 3.51
    Total Debt to Total Equity 0.11
    EBITDA Margin 9.90
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 157.28
    ROE % 11.02
    ROCE % 13.14
    Total Debt to Total Equity 0.17
    EBITDA Margin 21.10
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 138.61
    ROE % 8.39
    ROCE % 10.74
    Total Debt to Total Equity 0.13
    EBITDA Margin 20.23
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 122.53
    ROE % 8.41
    ROCE % 9.89
    Total Debt to Total Equity 0.11
    EBITDA Margin 18.63
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 112.65
    ROE % 6.18
    ROCE % 7.82
    Total Debt to Total Equity 0.10
    EBITDA Margin 14.92
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 105.16
    ROE % 3.32
    ROCE % 4.20
    Total Debt to Total Equity 0.09
    EBITDA Margin 11.90
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 9.84
    Total Assets 312.78
    Total Liabilities 312.78
    Total Equity 200.45
    Share Outstanding 1
    Price to Book Ratio 2.30
    Return on Assets (%) 8.53
    Return on Capital (%) 10.69
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 19.64
    Total Assets 240.06
    Total Liabilities 240.06
    Total Equity 175.67
    Share Outstanding 1
    Price to Book Ratio 2.81
    Return on Assets (%) 6.08
    Return on Capital (%) 7.04
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 19.97
    Total Assets 219.52
    Total Liabilities 219.52
    Total Equity 150.57
    Share Outstanding 1
    Price to Book Ratio 1.14
    Return on Assets (%) 4.75
    Return on Capital (%) 6.05
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 10.06
    Total Assets 209.84
    Total Liabilities 209.84
    Total Equity 140.29
    Share Outstanding 1
    Price to Book Ratio 1.49
    Return on Assets (%) 3.51
    Return on Capital (%) 4.58
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 12.50
    Total Assets 203.17
    Total Liabilities 203.17
    Total Equity 129.47
    Share Outstanding 1
    Price to Book Ratio 0.77
    Return on Assets (%) 1.85
    Return on Capital (%) 2.61
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 7.45
    Total Assets 358.15
    Total Liabilities 358.15
    Total Equity 252.94
    Share Outstanding 1
    Price to Book Ratio 2.30
    Return on Assets (%) 8.69
    Return on Capital (%) 10.32
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 18.62
    Total Assets 287.47
    Total Liabilities 287.47
    Total Equity 222.92
    Share Outstanding 1
    Price to Book Ratio 2.81
    Return on Assets (%) 6.11
    Return on Capital (%) 6.91
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 17.96
    Total Assets 252.41
    Total Liabilities 252.41
    Total Equity 195.93
    Share Outstanding 1
    Price to Book Ratio 1.14
    Return on Assets (%) 6.22
    Return on Capital (%) 7.22
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 2.44
    Total Assets 232.29
    Total Liabilities 232.29
    Total Equity 178.03
    Share Outstanding 1
    Price to Book Ratio 1.49
    Return on Assets (%) 4.53
    Return on Capital (%) 5.31
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 5.77
    Total Assets 195.84
    Total Liabilities 195.84
    Total Equity 162.93
    Share Outstanding 1
    Price to Book Ratio 0.77
    Return on Assets (%) 3.14
    Return on Capital (%) 3.47
    Particulars MAR 2025 (Values in Cr)
    Net Income 34.47
    Cash from Operations 26.01
    Cash from Investing -39.94
    Cash from Financing 13.24
    Net change in Cash -9.16
    Free Cash Flow 72.88
    Particulars MAR 2024 (Values in Cr)
    Net Income 19.35
    Cash from Operations 5.50
    Cash from Investing -8.15
    Cash from Financing 8.80
    Net change in Cash -0.88
    Free Cash Flow 11.95
    Particulars MAR 2023 (Values in Cr)
    Net Income 12.01
    Cash from Operations 6.91
    Cash from Investing 7.91
    Cash from Financing -0.71
    Net change in Cash 9.78
    Free Cash Flow 10.72
    Particulars MAR 2022 (Values in Cr)
    Net Income 9.61
    Cash from Operations 8.31
    Cash from Investing -15.25
    Cash from Financing 7.02
    Net change in Cash -2.43
    Free Cash Flow 16.52
    Particulars MAR 2021 (Values in Cr)
    Net Income 5.11
    Cash from Operations 46.67
    Cash from Investing -37.56
    Cash from Financing 1.61
    Net change in Cash 9.70
    Free Cash Flow 82.96
    Particulars MAR 2025 (Values in Cr)
    Net Income 40.68
    Cash from Operations 23.70
    Cash from Investing -41.42
    Cash from Financing 15.65
    Net change in Cash -10.54
    Free Cash Flow 70.57
    Particulars MAR 2024 (Values in Cr)
    Net Income 23.35
    Cash from Operations 4.45
    Cash from Investing -8.70
    Cash from Financing 11.40
    Net change in Cash 0.11
    Free Cash Flow 10.97
    Particulars MAR 2023 (Values in Cr)
    Net Income 19.44
    Cash from Operations 10.42
    Cash from Investing 6.24
    Cash from Financing 3.04
    Net change in Cash 15.38
    Free Cash Flow 13.97
    Particulars MAR 2022 (Values in Cr)
    Net Income 13.92
    Cash from Operations 7.74
    Cash from Investing -16.08
    Cash from Financing 7.55
    Net change in Cash -3.32
    Free Cash Flow 15.94
    Particulars MAR 2021 (Values in Cr)
    Net Income 7.50
    Cash from Operations 7.13
    Cash from Investing -5.34
    Cash from Financing 2.27
    Net change in Cash 3.05
    Free Cash Flow 7.55
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 34.87 14.47 1.68 267.22 23.12 38.85
    BLISS GVS PHARMA LTD. 467.40 37.63 4.16 4965.84 118.35 552.90
    CIPLA LTD 1472.95 33.25 3.45 118991.58 1165.55 1672.20
    FERMENTA BIOTECH LIMITED 501.25 23.44 3.62 1475.23 256.40 507.20
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 34.87 24.38 4.49 267.22 23.12 38.85
    AMRUTAJAN HEALTH LTD 515.00 23.08 4.02 1488.90 490.00 789.95
    ASTRAZENECA PHARMA INDIA LTD. 8103.65 105.90 23.21 20259.13 7630.00 9850.00
    BLISS GVS PHARMA LTD. 467.40 50.58 4.29 4965.84 118.35 552.90

    KILITCH DRUGS INDIA LTD shareholding pattern

    Holding
    36.1%
    63.77%
    0.11%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    KILITCH DRUGS INDIA LTD Technicals Summary

    190.70 2.20 redarrow
    red-green-graph indicator
    0 Bearish
    16 Bullish
    • 5 Days 185.70
    • 26 Days 183.20
    • 10 Days 184.00
    • 50 Days 180.00
    • 12 Days 183.80
    • 100 Days 175.10
    • 20 Days 183.50
    • 200 Days 173.60
    188.50 PIVOT
    First Support 183.09 First Resistance 191.99 Second Support 179.60 Second Resistance 197.40 Third Support 174.19 Third Resistance 200.89
    RSI 53.54 ADX 30.30 MACD 0.61 Williams % R -32.40 Commodity Channel Index (CCI) 112.04
    Date 2025-05-29 Week 41415.00 Same Day 33581.00 Month 34706.00
    1 Year 1.07 3 Year 0.82
    Over 1 Month
    -4.18% down
    Over 1 Year
    -15.37% down
    Over 3 Months
    21.14% down
    Over 3 Years
    26.99% down
    Over 6 Months
    15.12% down
    Over 5 Years
    12.20% down

    KILITCH DRUGS INDIA LTD Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    20 Sep 2019 0.5 Final 24 Sep 2019 Equity shares
    18 Sep 2018 0.5 Final 20 Sep 2018 Equity shares
    24 Sep 2012 30.0 Special 25 Sep 2012 Equity shares
    18 Aug 2011 1.0 Final 23 Aug 2011 Equity shares
    14 Oct 2010 1.0 Final 15 Oct 2010 Equity shares
    10 Sep 2009 1.0 Final 12 Sep 2009 Equity shares
    10 Sep 2008 1.0 Final 12 Sep 2008 Equity shares
    15 Nov 2007 1.0 Interim 16 Nov 2007 Equity shares
    Ex-Date Ex-Bonus Ratio
    24 Mar 2026 24 Mar 2026 1:1
    Dividend date Dividend amount Dividend type Record date Instrument type
    20 Sep 2019 0.5 Final 24 Sep 2019 Equity shares
    18 Sep 2018 0.5 Final 20 Sep 2018 Equity shares
    24 Sep 2012 30.0 Special 25 Sep 2012 Equity shares
    18 Aug 2011 1.0 Final 23 Aug 2011 Equity shares
    14 Oct 2010 1.0 Final 15 Oct 2010 Equity shares
    10 Sep 2009 1.0 Final 12 Sep 2009 Equity shares
    10 Sep 2008 1.0 Final 12 Sep 2008 Equity shares
    15 Nov 2007 1.0 Interim 16 Nov 2007 Equity shares
    Ex-Date Ex-Bonus Ratio
    24 Mar 2026 24 Mar 2026 1:1

    Top Gainers

    Top Losers

    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Kilitch Drugs (India) Ltd?

    Answer Field

    Kilitch Drugs (India) Ltd share price is for NSE ₹ 190.00 & for BSE ₹ 186.15 as on Aug 03 2026 01:48 PM.

    What is the Market Cap of Kilitch Drugs (India) Ltd Share?

    Answer Field

    The market cap of Kilitch Drugs (India) Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Aug 03 2026 01:48 PM.

    What is the 52 Week High and Low of Kilitch Drugs (India) Ltd?

    Answer Field

    The 52 Week High and Low of Kilitch Drugs (India) Ltd for NSE is ₹ 227.23 and ₹ 117.25 and for BSE is ₹ 226.50 and ₹ 121.10.

    What is 1 year return for Kilitch Drugs (India) Ltd?

    Answer Field

    The 1 year returns on the stock has been -15.37%.

    What is the P/E Ratio of Kilitch Drugs (India) Ltd Share?

    Answer Field

    As on Aug 03 2026 01:48 PM the price-to-earnings (PE) ratio for Kilitch Drugs (India) Ltd share is 20.47.

    What is the PB ratio of Kilitch Drugs (India) Ltd Share?

    Answer Field

    As on Aug 03 2026 01:48 PM, the price-to-book (PB) ratio for Kilitch Drugs (India) Ltd share is 95.25.

    How to Buy Kilitch Drugs (India) Ltd Share?

    Answer Field

    You can trade in Kilitch Drugs (India) Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Kilitch Drugs (India) Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Kilitch Drugs (India) Ltd shares on the Bajaj Broking app, follow these steps:

    1. Login to the Bajaj Broking App

    2. Click on the Search Icon

    3. Search “Kilitch Drugs (India) Ltd”

    4. Click on the BUY icon

    5. Place a buy order specifying the desired quantity of shares.

    6. Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |